SANTA MONICA, Calif., Feb. 28 /PRNewswire-USNewswire/ -- Closer analysis of the patent office "non-final" decision on a human embryonic stem cell patent held by the Wisconsin Alumni Research Foundation (WARF) shows the following gains made for researchers:
-- The original broad patent was abandoned showing it was underserved and new amended claims have been narrowed.
-- The original patent covered all embryonic stem cells no matter how they are derived, but the amended "non-final" ruling, while permitting the patent, narrowed the claim only to stems cells derived from pre-implantation embryos.
-- The newest stem cell research technology -- Induced Pluripotent Stem Cells (IPS cells) -- would clearly not be covered by the narrowed patent.
-- Stem cells derived from fetal tissue could have been claimed under the old patent, but now cannot be.
Consumer groups still believe the narrowed patent is invalid and should be revoked. They intend to challenge the latest patent office decision.
The challenge brought by the Foundation for Taxpayer and Consumer Rights (FTCR) and the Public Patent Foundation (PUBPAT) already produced a major victory for consumers and researchers when WARF announced in January 2007 that it was substantially easing its licensing requirements on stem cells. The groups filed re-examination requests on three patents, the '913, '806 and '780 in July 2006.
"We've made progress in thwarting WARF's overreaching patents and changing the organization's aggressive behavior toward the research community," said John M. Simpson, FTCR Stem Cell Project Director. "We are in this for the long haul."
The groups said they would appeal any later final decision by the
examiner supporting the amended claims to the Patent and Trademark Office's
Board of Appeals, which frequently overturns the decision made by
examiners. The groups also have the right to appeal any decision of that
board to the U
|SOURCE Foundation for Taxpayer and Consumer Rights|
Copyright©2008 PR Newswire.
All rights reserved